Correia Bernardo, Torres Tiago
Instituto de Ciências Biomédicas Abel Salazar, Universidade do Porto, Portugal.
Acta Biomed. 2015 Sep 14;86(2):121-9.
Psoriasis has been associated with several cardiometabolic comorbidities as well as clinically significant increased risk of cardiovascular disease and mortality. Obesity seems to have a key role in linking psoriasis and cardiovascular disease. There are a growing number of epidemiological studies associating psoriasis and obesity. The mechanism responsible for this association is not certain, but it is probably multifactorial, involving genetic, environmental and immune-mediated factors. Nonetheless, the chronic inflammatory state associated with obesity appears to be a key component of this relationship. Obesity is, therefore, a major factor in the management of psoriatic patients, with implications in treatment efficacy and safety. Moreover, weight loss has been shown to have a positive effect on psoriasis severity and response to treatment. The aim of this review is to synthesize the current evidence on the association between psoriasis and obesity, exploring the physiopathological mechanisms that link both diseases and highlighting the importance of obesity control in the efficacy and safety of systemic treatment of psoriasis. All clinicians must be aware of this association, so they can recognize it and provide the patients a proper follow-up and multidisciplinary approach when needed.
银屑病与多种心血管代谢合并症相关，同时心血管疾病和死亡率的临床显著风险也会增加。肥胖似乎在银屑病与心血管疾病的关联中起关键作用。越来越多的流行病学研究将银屑病与肥胖联系起来。这种关联的机制尚不确定，但可能是多因素的，涉及遗传、环境和免疫介导因素。尽管如此，与肥胖相关的慢性炎症状态似乎是这种关系的关键组成部分。因此，肥胖是银屑病患者管理中的一个主要因素，对治疗效果和安全性都有影响。此外，体重减轻已被证明对银屑病严重程度和治疗反应有积极影响。本综述的目的是综合目前关于银屑病与肥胖关联的证据，探讨连接这两种疾病的生理病理机制，并强调控制肥胖在银屑病系统治疗的疗效和安全性方面的重要性。所有临床医生都必须意识到这种关联，以便他们能够识别它，并在需要时为患者提供适当的随访和多学科治疗方法。
